Tocotrienols in Cardiometabolic Medicine: Beyond Classical Vitamin E Activity - Insights from Recent Randomized Controlled Trials and Future Clinical Directions

Abstract

Background: Tocotrienols, lesser-studied members of the vitamin E family, have gained attention because of their pleiotropic biological activities and potential role in cardiometabolic disease. Recent randomized controlled trials (RCTs) indicate benefits beyond α-tocopherol, including antioxidant, anti-inflammatory, and metabolic effects. Aim: To summarize RCT evidence published between 2020 and 2025 on the effects of tocotrienol supplementation in metabolic syndrome, type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), and diabetic complications. Methods: This narrative review included RCTs evaluating tocotrienol supplementation in adults with metabolic disorders. Outcomes included oxidative stress, inflammation, glycaemic control, lipid metabolism, vascular and neural function, and liver injury. Owing to heterogeneity in formulations, doses, and study designs, findings were synthesized narratively. Results: Tocotrienol supplementation improved biomarkers of oxidative stress, inflammation, and metabolic regulation. In metabolic syndrome, it modulated microRNAs associated with insulin resistance and inflammation. In T2D, δ-tocotrienol reduced HbA1c, fasting glucose, insulin resistance, and malondialdehyde while increasing antioxidant capacity. In NAFLD, δ-tocotrienol reduced inflammatory cytokines and liver injury markers more effectively than α-tocopherol. Tocotrienol-rich vitamin E also improved nerve conduction in diabetic neuropathy and supported renal function in diabetic kidney disease. Supplementation was well tolerated. Conclusions: Tocotrienols show promising metabolic, anti-inflammatory, and organ-protective effects, particularly in T2D and NAFLD. However, heterogeneity, small sample sizes, and short intervention periods limit definitive conclusions. Larger, standardized, long-term RCTs are needed to confirm their role as adjunctive therapy in cardiometabolic disease.